Latest News
Novartis bolsters radioligand portfolio with $1bn Mariana buy
Novartis bolsters radioligand portfolio with $1bn Mariana buy
Novartis will acquire Mariana Oncology, a Watertown, Massachusetts-based biotech company dealing in radioligand therapies (RLTs) to treat cancer.
.jpg?width=300&auto=webp&quality=80&disable=upscale)
Deal-Making
Sanofi has signed a licensing deal worth up to $1.2 billion with Novavax to commercialize the latter’s adjuvanted COVID-19 vaccine and use the technology to create its own flu shot.
Contract development and manufacturing organization (CDMO) Minaris has manufactured the first commercial batch of bluebird bio’s sickle cell disease drug Lyfgenia.
Facilities & Capacity
.jpg?width=700&auto=webp&quality=80&disable=upscale)
Solvias will open a biotech site in Research Triangle Park, North Carolina to enhance its analytical testing services for the cell and gene therapy (CGT) and biologics space.
CDMO Grand River Aseptic Manufacturing (GRAM) is constructing a syringe and cartridge filling center for its biologics pipeline and drug delivery systems.
Global Markets
At The London Biotechnology Show 2024, Microsoft's Thomas Balkizas emphasized AI's burgeoning impact on healthcare, from clinical trials to personalized medicine.
A panel of experts at LSX World Congress in London, UK discussed the importance of diversity and inclusion in teams and shared advice on how to attract and hire diverse talent.
Regulations
The US FDA has approved Beqvez (fidanacogene elaparvovec), Pfizer’s adeno-associated virus (AAV) based gene therapy for the treatment of hemophilia B.
CDMO AGC Bio will supply lentiviral vectors for Orchard Therapeutics’ metachromatic leukodystrophy (MLD) gene therapy, approved in the US this week.
Therapeutic Class
Sanofi has signed a licensing deal worth up to $1.2 billion with Novavax to commercialize the latter’s adjuvanted COVID-19 vaccine and use the technology to create its own flu shot.
Singapore’s SCG Cell Therapy and A*STAR, an official Singapore investor, will team up to build new joint laboratory research labs for cellular immunotherapies.
Upstream & Downstream Processing
Repligen says it is looking at new modalities and its filtration franchise to drive momentum following a mixed first quarter 2024.
Through changing the traditional organizational structure to include all functions in one team, the setup can support complexities in manufacturing projects, says Boehringer Ingelheim.